THE INNOVATION OF ESTEVE IS RECOGNIZED AGAIN AS EXCELLENT BY PROFARMA
Esteve has been rated again as "Excellent" in terms of R&D by the Profarma Plan of the Ministry of Industry. This recognition is the 30th that the company has received uninterrupted since Profarma began these evaluations in 1986.
The Profarma Plan (2013-2016) places ESTEVE in Group A (Excellent), a classification that recognizes the success of truly innovative pharmaceuticals which clearly bets on research with its own pharmaceutical plant or own R&D center. In this way, ESTEVE reaches the highest score among the more than 50 companies in the sector that Profarma analyzes.
Profarma is a call that unites the will of the Minister of Industry, Energy and Tourism; Economy and Competitiveness and Health, Social Services and Equality, to promote the competitiveness of the Pharmaceutical Industry with the approval of the Delegated Commission of the Government for Economic Affairs. Its main goal is to stimulate the competitiveness of the sector through the modernization of its companies and to support the activities with greater added value.
Innovation has been the driving force behind ESTEVE and its growth since its beginnings in 1929. Today, it works with a portfolio of innovative projects that seek to provide solutions to medical needs not adequately covered and with a great social impact.
You can follow ESTEVE on Twitter: twitter.com/esteve_news.
ESTEVE APPOINTS JORDI MUNTAÑOLA AS CHIEF COMMERCIAL OFFICER FOR EUROPE
Jordi Muntañola will take on the leadership of all the pharmaceutical activities in Spain and Europeread more
POMPEU FABRA UNIVERSITY AND ESTEVE ARE TO INVESTIGATE NEW TARGETS FOR TREATING NEUROPATHIC PAIN
The RIBOPAIN project aims to identify new therapeutic solutions for pain and to develop more effective drugsread more
ESTEVE ANNOUNCES A RESTRUCTURING OF ITS PHARMACEUTICAL ACTIVITY
Esteve Pharmaceuticals submits a reduction in force (RIF) which will affect 103 jobs in Spainread more